【The efficacy and action of Betahistine Mesylate Tablets】_Benefits _Efficacy

From: https://www.diseasewiki.com

The efficacy and action of Betahistine Mesylate Tablets

Betahistine Mesylate Tablets are a cardiovascular improver, mainly used to treat dizziness and vertigo. It is a commonly used clinical medicine, and many people want to use it to treat their own diseases. So, how good is the effect of Betahistine Mesylate Tablets? How long does it take to take effect? Let’s find out quickly.

Betahistine Mesylate Tablets are indicated for secondary dizziness and vertigo due to the following diseases, including Meniere’s disease, Meniere’s syndrome, and vertigo.

In the treatment of this aspect, Betahistine Mesylate Tablets have a certain effect.

The dosage and administration of Betahistine Mesylate Tablets are as follows: generally, adults take 1-2 tablets per time (the dose of Betahistine Mesylate per time is 6-12mg), three times a day after meals, and the dosage can be adjusted according to age and disease condition. Betahistine Mesylate Tablets are contraindicated in patients with a high sensitivity to Betahistine Mesylate or any excipients in the formula.

How long to take it is reasonable depends on the patient’s condition.

Caution should be exercised when administering the following patients:

1. Patients with gastrointestinal ulcers or active gastrointestinal ulcers.

{Due to the nitrosamine-like effect of Betahistine Mesylate Tablets, it may cause gastric juice metabolism by affecting H2 protein kinase}

2. Patients with bronchial asthma.

{Due to the nitrosamine-like effect of Betahistine Mesylate Tablets, it may cause respiratory system constriction by affecting H2 protein kinase}

3. Patients with adrenal medullary tumors.

{Due to the nitrosamine-like effect of Betahistine Mesylate Tablets, it may cause excessive adrenal hormone metabolism and increase blood pressure}

On the side effects level, be alert: Among a total of 2,254 cases, 26 cases (1.15%) reported side effects (post-marketing clinical medicine investigation report):

Gastrointestinal tract: Occasionally (0.1% – 5%) nausea and vomiting.

Skin allergy: Occasionally (0.1% – 5%) rash.